Current Headlines

  1. Sartorius Stedim Biotech Further Develops Its In-Situ Sterilizable Fermenter/Bioreactor BIOSTAT D-DCU

    Sartorius Stedim Biotech, a leading global supplier of the biopharmaceutical industry, has launched a new version of its proven stainless steel fermentor/bioreactor BIOSTAT D-DCU.

  2. Study Showing How Stem Cells Slow Aging May Lead To New Heart Failure Treatments

    A new study published in STEM CELLS Translational Medicine demonstrates how mesenchymal stem cells (MSCs) not only protect the heart from further damage after a cardiac incident but can actually slow down its aging process, too.

  3. SAFC Launches New EX-CELL Advanced Products For Scalable, Efficient Biopharmaceutical Manufacturing

    Sigma-Aldrich Corporation recently announced that SAFC Commercial, the Company’s business unit providing products and services for use in regulated pharmaceutical and biopharmaceutical applications, has launched the EX-CELL Advanced product line.

  4. Brain Cells Can 'Wait' To Hear

    Cells in the brainstem that underlie sound localization, compare signals at the two ears and can pause while doing so.

  5. Worthington Announces New Line Of Animal/Xeno-Free Enzymes Reducing Risk Of Contamination In Applications From Primary Stem Cell Research To Bioprocessing

    Worthington announced recently the introduction of several new grades of Collagenase, recombinant Nucleases DNase I and RNases A, T1 & T2 and Neutral Protease (Dispase).

  6. Pall Corporation Acquires BioSMB Technology From Tarpon Biosystems To Expand Downstream Continuous Processing Capabilities

    Pall Corporation, a global leader in filtration, separation and purification, announces the acquisition of the BioSMB technology platform from Tarpon Biosystems. These chromatographic systems enable single-use, multicolumn chromatography for process development and are well placed for multiproduct and single-use facilities.

  7. Aduro Biotech Establishes Major Collaboration With Novartis For Global Research, Development And Commercialization Of Immuno-Oncology Products Derived From Its Proprietary STING-Targeted CDN Platform Technology

    Aduro Biotech, Inc. recently announced the establishment of a major collaboration with Novartis for the worldwide research, development and commercialization of novel immuno-oncology products derived from Aduro’s cyclic dinucleotide (CDN) approach to target the STING (Stimulator of Interferon Genes) receptor, that, when activated, is known to initiate broad innate and adaptive tumor-specific immune responses.

  8. Marken Wins As Best Life Science Logistics Service Provider Second Year In A Row

    Marken announced recently that they won the pharmaceutical clinical research industry award of Best Life Science Logistics Provider at the 5th Annual BioPharma Asia Industry Awards. 

  9. EMD Millipore Granted Patent For Selective Layering Method That Improves The Consistency Of Virus Filtration Performance

    EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, has been granted a United States patent for developing a selective layering method that significantly improves the consistency of virus filtration performance.

  10. ISPE Announces 2015 Facility of the Year Award Winners

    The 11th annual ISPE Facility of the Year Awards (FOYA) program today announced its 2015 FOYA Category Award winners: AstraZeneca China (Project Execution), Astellas Pharma, Inc. (Equipment Innovation) and IDT Biologika GMbH (Facility Integration). 

Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.